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The results of the UK small aneurysm trial were
published for the first time in 1998,1 and the long-term
results were published in 2002.2
The crude results presented in the above two articles
may be summarized as follows. No significant
difference in overall survival between the two groups;1
impaired quality of life in the surveillance group;3
improved long-term survival by early surgery.2 The
investigators conclude: ‘results do not support a policy
of open surgical repair for abdominal aortic aneur-
ysms of 4.0–5.5 cm in diameter’.1
One critical remark made immediately was the 5.8%
mortality observed after elective surgery which is
higher than usual in major vascular surgical centres;
nevertheless, we agree with the investigators that, if
this rate is higher than the ones observed in some
reference centres,4 it reflects reality in the geographical
area where the trial is conducted and is comparable
with the mortality rate observed in community
studies.5 Moreover, the results of the ADAM US
study following the same design were published in
2002. With a 2.7% in-hospital surgical mortality no
difference was observed between the two groups.6
Concluding, evidence-based medicine cut it short:
no benefit from surgery versus surveillance for
aneurysms below 55 mm in diameter. Are things that
simple?
External Validity of the Design
The trial was designed to have 80% power to show a
significant difference at the 5% level.1 The investi-
gators concluded that there was no difference between
the two groups. They proceeded like they would have
in a trial of equivalence although they deal with a trial
conceived to show superiority. Question: is there really
no difference or is the power of the study insufficient to
show a difference?
In 2002, the long-term outcomes of the study were
published.2 The crude results show that at 8 years the
mortality rate was 7.2% lower ðp ¼ 0:03Þ in the early-
surgery group. Another interesting data is that rupture
risk was four times higher among women than men.
We can read this sentence which is a masterpiece of
ambiguity: ‘Among patients with a small abdominal
aortic aneurysm, we found no long-term difference in
mean survival between the early-surgery and surveil-
lance groups, although after 8 years, total mortality
was lower in the early-surgery group’.2 Should we
imagine that the magic of evidence-based medicine
has created that survival, and the mortality is an
unrelated phenomenon? The investigators propose
three hypotheses to explain this difference and finally
reject them to retain a fourth one: lifestyle related to
early surgery could underlie the long-term survival
benefit from early surgery. This is credible. But, even if
the reasons for this higher survival are probably
multifactorial, the investigators conceal another
simple hypothesis. The UK small AAA trial is a trial
of superiority; as previously stated the power of the
study does not allow a difference at five years to show.
At 8 years the power of the study is higher and a
statistically significant superiority becomes ‘evident’
in the early-surgery group. Thus, the conclusion could
be that early surgery is the best treatment, but the
benefit compared with surveillance is slight. This is the
same kind of situation we know in the ‘carotid’ trials
for asymptomatic stenosis and symptomatic stenosis
between 50 and 69%: a theoretical but thin benefit from
surgery.
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Internal Validity of the Design
(a)One problem is the credibility of a sharp barrier
defined by a duplex measure. Can we really
imagine that when an aneurysm grows from 55 to
56 mm the patient’s fate is immediately changed
and surgery must be prompted? Another problem
is the accuracy of the diameter measured by
ultrasounds. In the UK trial, the examiners were
selected according to both the observer’s perform-
ance and the machine; despite that, the accuracy of
the result obtained was plus or minus 2 mm.1 The
question is how to apply the trial conclusion to
aneurysms measuring between 53 and 57 mm?
(b)The primary end point of the trial is death, whether
or not due to aneurysm rupture. There were 150
deaths in the surveillance group: 17 due to ruptures,
one from unknown cause, and the rest attributed to
other causes. The autopsy rate in the trial is 29%.
Thus 94 primary events are labelled according to
the death certificate. Everyone knows that AAA
rupture may masquerade a cardiac event.
(c)Among the 527 patients under randomized surveil-
lance, 38 were operated on without fulfilling the
criteria for surgery. In the 563 patients undergoing
randomized early surgery, 43 patients were not
operated on. Globally, these violations of protocol
due to cross-over represent 7% of the enrolled
patients. In a study where the difference is small or
nil, 7% is largely enough to change the conclusions.
Although this is a study based on the intention to
treat, it would have been interesting to compare the
results with a perprotocol study taking into account
only the patients complying to the protocol. Look-
ing at the data published it is impossible to establish
the consequence of the cross-over patients on the
study power.
(d)Another shortcoming of the trial is that conclusions
cannot be applied to women. The UK trial
comprised only 17% women and 1% in the US trial.
Interpretation and Comments
One has to keep in mind that the cause of death due to
rupture may lead to misclassification, so overall
mortality could be a better end point than AAA
specific mortality in areas with a low autopsy rate.
That is what the investigators did, but this basic weak
spot should have been discussed and should have led
the investigators to temper their conclusion.
The UK small AAA trial as well as the ADAM trial
used screening to enrol a substantial number of their
participants. The consequence must be a smaller mean
size of AAA compared to non-screening areas. If we
believe a 5.4 cm AAA has a higher risk of rupture than
a 4.0 cm AAA, the overall conclusion may not be true
in a non-screened population.
In reply to a critique on subgroup analysis,7 the
investigators strike with arrogance ‘there is no
scientific validity for conducting subgroup analysis
of the trial data’. Nevertheless, they observe [Ref. 1,
Table 2] that there is a lower death risk in the early-
surgery group for patients aged under 70 and for AAA
between 50 and 55 mm (Table 1). These data suggest a
benefit in the early-surgery group for aneurysms
above 50 mm and for the younger patients. Question:
would an analysis corresponding to this subgroup of
patients show the same results?
An important observation is the low rate of
ruptures (2.3%) observed during the trial, which may
explain the faint role of prophylactic surgery. This low
rate is realistic unless there are unknown ruptures in
the large group of deaths attributed to other causes. It
is interesting to be reminded that during the same time
the randomized trial was running, the trial coordina-
tors followed another cohort of 1167 patients ineligible
for randomization.8 The populations of the two groups
(1090 randomized patients and 1167 non-randomized
patients) were comparable, but the rate of rupture in
the non-randomized population was 6.7% (78/1167).8
The difference may be explained by the scrutiny of
surveillance in the UK trial. Question: is this kind of
surveillance realistic on a nation-wide scale?
In addition to the burden on the patient, Valentine
showed in a study conducted in the Veterans
Administration that one third of the candidates for
watchful waiting programmes were unable to partici-
pate.9
Beyond the meanders of statistics we would like to
look at things from the patient’s view. The final results
of the trial show that after three years 78% of all
patients enrolled were operated on, and 84% after six
years. During the entire trial, 25 ruptures occurred
either for patients under surveillance or for those not
operated on under randomized surgery. The non-
operated patients were obliged to follow a duplex
surveillance, for some of them every three months,
with a 70–80% chance to be operated on within a 3–4
year period. We can also say that one patient out of five
Table 1. Decrease of death risk by subgroups1
Age Surveillance Early surgery Hazard ratio 95% CI
60–66 42/181 36/181 0.76
67–71 60/180 51/183 0.80
Aneurysm diameter (mm)
49–55 52–145 51/174 0.79
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will have the chance to live for 4 years with a duplex
every 3 months, in fear of rupture, and being almost
certain to be operated at the end of the story.
And finally, here is the investigator’s point of view.
The first objective of the UK small AAA trial was ‘to
determine whether early elective surgery or a period
of US surveillance provides the better management of
small asymptomatic AAA…’.10 One wonders whether
the investigator’s attitude is neutral or if their inmost
thoughts are to demonstrate that early surgery must be
condemned. They righteously defend the surprisingly
high mortality rate due to a pragmatic attitude in their
approach to recruitment and fitness for surgery.1 If the
‘no selection’ of surgeons is pragmatic, can we say that
the selection of duplex specialists and the frequency of
surveillance are pragmatic? Do all the duplex special-
ists in the country obtain the same accuracy of plus or
minus 2 mm? Are all the patients screened with a 40–
55 diameter aneurysm as compliant as the ones
enrolled in the trial after having signed an informed
consent?
According to objective number one of the trial,10 the
investigators assess the quality of life and conclude
there was a benefit after 12 months in the early surgery
group.3 Immediately after that, they add this comment
‘for families who have lost a loved one after surgery,
quality of life may have deteriorated substantially’.
Did they think of the families who have lost a loved
one after rupture?
In a correspondence, the investigators say ‘this may
be a British prerogative, better to understate than
overstate’.7 In this case, to claim clear-cut conclusions
from this trial is clearly an overstatement. As the
ADAM investigators say ‘arbitrarily setting a single
threshold diameter for elective AAA repair in all
patients is naı¨ve’.6
We must thank and congratulate the UK small
aneurysm trial investigators for their splendid job and
for the large amount of knowledge with which they
provided us. But we would advise them to be more
modest and change their diktats for more pragmatic
conclusions. Diameter measurement, especially with
duplex, is always an approximation; the crude number
must be replaced in the context of the patient.
Surveillance is an acceptable alternative for AAA
between 40 and 55 mm, probably the best alternative
for high risk patients. Surgery is the more reasonable
solution for good risk patients with an AAA .50 mm.
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